President Donald J. Trump
The White House
Fact Sheets

Fact Sheet: President Donald J. Trump Ensures American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve

The White House

BOLSTERING PHARMACEUTICAL SECURITY: Today, President Donald J. Trump signed an Executive Order to fill the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) with critical drug components, ensuring a resilient domestic supply chain for essential medicines.

  • The Order directs the Office of the Assistant Secretary for Preparedness and Response (ASPR), within the Department of Health and Human Services, to develop a list of approximately 26 critical drugs vital to national health and security, and ready the SAPIR repository to receive and maintain the Active Pharmaceutical Ingredients (APIs) used to make these critical drugs.
  • The Order charges the ASPR with obtaining a 6-month supply of these critical APIs, with a preference for obtaining domestically-manufactured APIs if possible, and placing them in the SAPIR.
  • It further instructs the ASPR to update the 2022 list of 86 essential medicines and propose a plan to obtain and store a 6-month API supply for these drugs.
  • ASPR shall further develop a proposal for opening a second SAPIR repository to further enhance pharmaceutical supply chain resilience.

ADDRESSING SUPPLY CHAIN VULNERABILITIES: Restoring capacity for domestic production of essential pharmaceutical products is essential to safeguarding national health and security against global supply chain disruptions.

  • Only about 10% of APIs for U.S. prescription drugs are manufactured domestically, leaving the Nation vulnerable to foreign supply chain disruptions.
  • The Biden Administration failed to advance domestic production or fill the SAPIR, despite spending billions on supply chain initiatives.
  • Overreliance on foreign, sometimes adversarial, nations for Key Starting Materials (the materials used to make APIs) and APIs risks shortages of essential medicines.
  • Stockpiling APIs, which are lower-cost and have longer shelf lives, strengthens the Nation’s ability to ensure access to critical drugs during emergencies.

RESTORING AMERICAN SELF-RELIANCE: President Trump has consistently prioritized policies to secure America’s pharmaceutical independence and ensure access to affordable, domestically produced drugs.

  • In 2020, President Trump signed an Executive Order directing his Administration to increase domestic procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs, as well as identify supply chain vulnerabilities.  
  • In 2020, President Trump created a SAPIR to stockpile APIs, laying the foundation for pharmaceutical resilience.
  • In May 2025, President Trump signed an Executive Order to remove regulatory barriers and facilitate the restoration of a robust domestic manufacturing base for prescription drugs, including key ingredients and materials necessary to manufacture prescription drugs.
  • In May 2025, President Trump signed an Executive Order implementing most-favored-nation drug pricing to lower the prices Americans pay, and later sent letters to 17 pharmaceutical companies to encourage competitive pricing and domestic production.